Lamivudine News and Research

RSS
Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

WHO revises treatment protocols for HIV patients

WHO revises treatment protocols for HIV patients

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.